Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PHARMA > SKELETAL 2 > Flashcards

SKELETAL 2 Flashcards

1
Q

Is characterized by the loss of cholinergic neurons in the nucleus basalis of Meynert

A

Alzheimer’s disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Is associated with a loss of dopaminergic neurons in the substantia nigra.

A

Parkinson’s disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

The most prevalent of Neurodegenerative Diseases

A

Alzheimer’s disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

2nd most prevalent neurodegenerative disorder

A

Parkinson’s disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Is a progressive neurological disorder of muscle movement, characterized by tremors, muscular rigidity, bradykinesia (slowness in initiating and carrying out voluntary movements), and postural and gait abnormalities. Most cases involve people over the age of 65.

A

Parkinsonism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Parkinsonism is correlated with destruction of ___ in the substantia nigra with a consequent reduction of dopamine actions in the corpus striatum parts of the brain’s basal ganglia system that are involved in motor control. Genetic factors do not play a dominant role of this, although they may exert some influence on an individual’s susceptibility to the disease.

A

dopaminergic neurons

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

The substantia nigra, part of the extrapyramidal system, is the source of dopaminergic neurons that terminate in the striatum. The dopaminergic system appears to serve as a tonic, sustaining influence on motor activity rather than participating in specific movements.

A

Substantia nigra

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Normally, it is connected to the substantia nigra by neurons that secrete the inhibitory transmitter GABA at their termini in the substantia nigra.

A

neostriatum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Cells of the substantia nigra send neurons back to the neostriatum, secreting the inhibitory transmitter ___ at their termini.

A

dopamine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Destruction of cells in the substantia nigra results in the degeneration of the nerve terminals responsible for secreting dopamine in the neostriatum.

A

Parkinson’s disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Parkinsonian symptoms infrequently follow viral encephalitis or multiple small vascular lesions.

A

Secondary parkinsonism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Drugs whose major pharmacologic action is blockade of dopamine receptors in the brain, may also produce parkinsonian symptoms. These drugs should not be used in parkinsonian patients.

A

phenothiazines and haloperidol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Is a metabolic precursor of dopamine. It restores dopaminergic neurotransmission in the corpus striatum by enhancing the synthesis of dopamine in the surviving neurons of the substantia nigra. Uses in early disease.

A

Levodopa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Side effects of Levodopa in large doses.

A
  • nausea,
  • vomiting,
  • cardiac arrhythmias, and
  • hypotension
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

A dopa decarboxylase inhibitor that does not cross the blood-brain barrier. It diminishes the metabolism of levodopa in the gastrointestinal tract and peripheral tissues; thus, it increases the availability of levodopa to the CNS.

A

Carbidopa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Decreases the rigidity, tremors, and other symptoms of parkinsonism.

A

Levodopa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Large, neutral amino acids (for example, leucine and isoleucine) compete with it for absorption from the gut and for transport across the blood-brain barrier. Thus, it should be taken on an empty stomach, typically 45 minutes before a meal.

A

levodopa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Adverse effect of Levodopa and carbidopa in the peripheral.

A
  • Anorexia
  • nausea
  • vomiting
  • tachycardia
  • ventricular systoles
  • hypotension
  • mydriasis
  • blood dyscasias
  • brownish saliva and urine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

CNS eefects of Levodopa and carbidopa

A
  • visual and auditory hallucinations
  • dyskinesias
  • overactivity of dopaine
  • mood changes, depression, psychosis and anxiety in levodopa
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

increases the peripheral breakdown of levodopa and diminishes its effectiveness

A

Vitamin pyridoxine (B6)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Concomitant administration of levodopa and ___, such as phenelzine, can produce a hypertensive crisis caused by enhanced catecholamine production; therefore, caution is required when they are used simultaneously.

A

monoamine oxidase (MAO) inhibitors

22
Q

Are generally contraindicated in parkinsonian patients, because these potently block dopamine receptors and produce a parkinsonian syndrome themselves.

A

Antipsychotic drugs

23
Q

Also called deprenyl, selectively inhibits MAO Type B (which metabolizes dopamine) at low to moderate doses but does not inhibit MAO Type A (which metabolizes norepinephrine and serotonin) unless given at above recommended doses, where it loses its selectivity.

A

Selegiline

24
Q

Selegiline has little potential for causing hypertensive crises but if taken at high doses, the selectivity of the drug is lost, and the patient is at risk

A

severe hypertension

25
Q

Selegiline is metabolized to ___, whose stimulating properties may produce insomnia if the drug is administered later than midafternoon.

A

methamphetamine and amphetamine

26
Q

an irreversible and selective inhibitor of brain (MAO) Type B, has five times the potency of selegiline. Unlike selegiline, it is not metabolized to an amphetamine-like substance.

A

Rasagiline

27
Q

inhibits Catechol-O-methyltransferase (COMT) → decreased plasma concentrations of 3-O-methyldopa → increased central uptake of levodopa → greater concentrations of brain dopamine

A

Entacapone or tolcapone

28
Q

Differs from entacapone in that the former penetrates the blood-brain barrier and inhibits COMT in the CNS. However, the inhibition of COMT in the periphery appears to be the primary therapeutic action.

A

Tolcapone

29
Q

does not exhibit this toxicity and has largely replaced tolcapone.

A

Entacapone

30
Q

Is associated with tolcapone use. Therefore, it should be used along with appropriate hepatic function monitoring only in patients in whom other modalities have failed.

A

fulminating hepatic necrosis

31
Q

An ergot derivative alkaloid and partial agonist at dopamine D2 receptors in the brain. The drug increases the functional activity of dopamine neurotransmitter pathways, including those involved in extrapyramidal function. It causes pulmonary and retroperitoneal fibrosis.

A

bromocriptine

32
Q

Effect of Bromocriptine in patients with peripheral vascular disease, a worsening of the ___ occurs, and in patients with peptic ulcer, there is a ___ of the ulcer.

A
  • vasospasm

- worsening

33
Q

Non-ergot alkaloid. Has high affinity for the dopamine D3 receptor. Effective as monotherapy in mild parkinsonism & can be used together with levodopa in more advanced disease.

A

Pramipexole

34
Q
  • Mental disturbances (confusion, delusions, hallucinations, impulsivity) are more common with pramipexole than with levodopa.
  • In rare cases, an uncontrollable tendency to fall asleep may occur.
  • may be neuroprotective because it is reported to act as a scavenger for hydrogen peroxide.
A

Pramipexole

35
Q
  • Non-ergot alkaloid
  • Has high affinity for the dopamine D2 receptor.
  • It is effective as monotherapy and can be used with levodopa to smooth out response fluctuations.
  • Metabolized by hepatic CYP1A2
A

Ropinirole

36
Q
  • A potent dopamine receptor agonist, apomorphine injected subcutaneously may provide rapid (within 10 min) but temporary relief (1–2 h) of “off-periods” of akinesia in patients on optimized dopaminergic therapy.
  • Because of severe nausea, pretreatment for 3 days with antiemetics is necessary.
  • Other side effects of apomorphine include dyskinesias, hypotension, drowsiness, and sweating.
A

Apomorphine

37
Q

Increasing the release of dopamine, blockading cholinergic receptors, and inhibiting the N-methyl-D-aspartate (NMDA) type of glutamate receptors. The drug may cause restlessness, agitation, confusion, and hallucinations, and at high doses, it may induce acute toxic psychosis.

A

Amantadine

38
Q

Antimuscarinic agents

A
  • benztropine,
  • trihexyphenidyl,
  • procyclidine, and
  • biperiden
39
Q
  • All of these drugs can induce mood changes and produce xerostomia (dryness of the mouth) and visual problems, as do all muscarinic blockers.
  • They interfere with gastrointestinal peristalsis and are contraindicated in patients with glaucoma, prostatic hyperplasia, or pyloric stenosis.
A

Antimuscarinic agents

40
Q

Blockage of ___ produces effects similar to augmentation of dopaminergic transmission

A

cholinergic transmission

41
Q

Dementia of the Alzheimer’s type has three distinguishing features:

A

1) accumulation of senile plaques (β-amyloid accumulations)
2) formation of numerous neurofibrillary tangles
3) loss of cortical neurons particularly cholinergic neurons

42
Q

Currently, four reversible AChE inhibitors are approved for the treatment of mild to moderate Alzheimer’s disease:

A

➢donepezil
➢galantamine
➢rivastigmine
➢tacrine

43
Q

Competitive and may also be acting as an allosteric modulator of the nicotinic receptor in the CNS and, therefore, secondarily increase cholinergic neurotransmission through a separate mechanism.

A

Galantamine

44
Q

Is associated with hepatotoxicity for AD drugs unlike the other drugs.

A

tacrine

45
Q

Stimulation of ___ in the CNS appears to be critical for the formation of certain memories but overstimulation suggested a mechanism for neurodegenerative or apoptotic.

A

glutamate receptors

46
Q

A dimethyl adamantane derivative that acts by physically blocking the NMDA receptor-associated ion channel partially. Often given in combination with an AChE inhibitor.

A

Memantine

47
Q

Which occupy and block nearly all NMDA receptor-associated ion channel channels.

A

phencyclidine

48
Q

NMDA-receptor antagonist is indicated for the management of amyotrophic lateral sclerosis (ALS). It blocks glutamate, sodium channels and calcium channels. It may improve the survival time and delay the need for ventilator support in patients suffering from ALS.

A

Riluzole

49
Q

Bradykinesia has made drug treatment necessary in a 60-year-old male patient with Parkinson’s disease, and therapy is to be initiated with levodopa. Regarding the anticipated actions of levodopa, the patient would not be informed that

(A) A netlike reddish to blue discoloration of the skin is a possible side effect
(B) Dizziness may occur upon standing up
(C) He should take the drug in divided doses to avoid nausea
(D) The drug will probably improve his symptoms for a period of time but not indefinitely
(E) Uncontrollable muscle jerks may occur

A

A netlike reddish to blue discoloration of the skin is a possible side effect

50
Q

The prescribing physician will (or should) know that levodopa

(A) Causes less severe behavioral side effects if given together with a drug that inhibits hepatic dopa decarboxylase
(B) Fluctuates in its effectiveness with increasing frequency a treatment continues
(C) Prevents extrapyramidal adverse effects of antipsychotic drugs
(D) Protects against cancer in patients with melanoma
(E) Has toxic effects, which include pulmonary infiltrates

A

Fluctuates in its effectiveness with increasing frequency a treatment continues

51
Q

Modest improvement in the memory of patients with Alzheimer’s disease may occur with drugs that increase transmission at which receptors?

A

Cholinergic

PHARMA (26 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions